Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03775954 |
Recruitment Status :
Recruiting
First Posted : December 14, 2018
Last Update Posted : March 20, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
High Risk Pregnancy Congenital Heart Disease Fetal Hydrops Twin Monochorionic Monoamniotic Placenta Gastroschisis Fetal Demise Stillbirth Fetal Arrhythmia Long QT Syndrome Intrauterine Fetal Death Sudden Infant Death Pregnancy Loss Twin Twin Transfusion Syndrome Birth Defect Fetal Cardiac Anomaly Fetal Cardiac Disorder Fetal Death Brugada Syndrome | Diagnostic Test: Fetal Magnetocardiogram and Neonatal Electrocardiogram |
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise |
Actual Study Start Date : | July 1, 2018 |
Estimated Primary Completion Date : | April 30, 2023 |
Estimated Study Completion Date : | April 30, 2023 |

Group/Cohort | Intervention/treatment |
---|---|
1) Fetal Congenital Heart Disease
Pregnancy with major fetal congenital heart disease, after 20 weeks gestation, and as neonate following delivery. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
|
Diagnostic Test: Fetal Magnetocardiogram and Neonatal Electrocardiogram
Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born. |
2) History of fetal demise (Stillbirth)
Pregnancy with a history of an unexplained fetal demise (stillbirth at 20 -40 weeks gestation) during any prior pregnancy. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
|
Diagnostic Test: Fetal Magnetocardiogram and Neonatal Electrocardiogram
Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born. |
3) Fetal hydrops, immune or non-immune
Pregnancy with fetal hydrops, immune or non-immune, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
|
Diagnostic Test: Fetal Magnetocardiogram and Neonatal Electrocardiogram
Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born. |
4) Fetal gastroschisis
Pregnancy with fetal gastroschisis, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
|
Diagnostic Test: Fetal Magnetocardiogram and Neonatal Electrocardiogram
Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born. |
5) Twin pregnancy, monochorionic
Twin pregnancy, monochorionic, with or without twin-twin transfusion syndrome, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (fMCG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
|
Diagnostic Test: Fetal Magnetocardiogram and Neonatal Electrocardiogram
Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born. |
- Heart rate variability using fMCG [ Time Frame: Comparison of procedures at approximately 20-27 weeks gestation, at 30-37 weeks gestation, and at neonatal ECG at 0-4 weeks of age ]To measure and compare the fMCG heart rate variability in five pregnancy conditions associated with fetal demise, to those of gestation matched normal fetuses.
- Cardiac conduction [ Time Frame: Comparison of cardiac time intervals at approximately 20-27 weeks gestation, 30-37 weeks gestation and at neonatal ECG at 0-4 weeks of age ]To measure and compare the fMCG cardiac time intervals in five pregnancy conditions associated with fetal demise, to those of gestation matched normal fetuses and to neonatal ECGs at 0-4 weeks of age.
- Cardiac repolarization [ Time Frame: Comparison of cardiac repolarization at approximately 20-27 weeks gestation, 30-37 weeks gestation and neonatal ECG at 0-4 weeks of age. ]To measure and compare the fMCG cardiac repolarization patterns in five pregnancy conditions associated with fetal demise, to those of gestation matched normal fetuses, and to neonatal ECGs at 0-4 weeks of age.
- Unique "signature" electrophysiologic abnormalities [ Time Frame: Comparison of findings at approximately 20-27 weeks gestation, 30-37 weeks gestation and neonatal ECG at 0-4 weeks of age ]
2a) To determine whether unique "signature" electrophysiologic abnormalities are present in any of these five maternal-fetal diseases, and 2b) to define at what trimester these develop. Understanding any unique findings could allow study of specific treatment strategies in the future.
findings are first seen.
- Pregnancy outcomes [ Time Frame: Comparison of findings at approximately 20-27 weeks gestation, 30-37 weeks gestation and neonatal ECG at 0-4 weeks of age ]To correlate fMCG findings with 3a) outcomes of pregnancies (fetal demise, premature delivery, small for GA, 5 minute APGAR < 5, neonatal death) and 3b) fMCG cardiac time intervals with postnatal ECG intervals at 0-4 weeks of age.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | This study involves pregnant women and subsequently-born neonate(s) of either gender. |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
Current pregnancy complicated by one of the five diagnostic categories
- prior unexplained Stillbirth at/after 20 weeks gestation
- fetal major congenital heart defect
- fetal hydrops
- fetal gastroschisis
- monochorionic twin pregnancy
- Subject must be 18 years of age or older
- Subject must be English speaking and must be able to read and sign the consent form in English
- Subject must be able to recline comfortably for 1-3 hours
- Subject must be willing to complete all three procedures (fMCG, fMCG, nECG) as per protocol, unless medically unable
- Subject must be willing to allow us to review her and her infants prenatal, deliver, and post-natal records to verify diagnosis, and clinical findings.
Exclusion Criteria:
- Severe claustrophobia not reduced by taking breaks, or by having the light on, or by having someone in the room with them.
- Active labor
- Acute illness
- Unable to recline comfortably with a pillow for more than 1-3 hours (assuming some breaks are provided)
- Weight over 450 lbs
-
An electric stimulation device (TENS unit, pacemaker, or nerve stimulator) that could produce electric or magnetic noise.
- Note that the Tristan 624 Magnetometer does not pose a risk to the subject's device, (since fMCG does not produce any energy or magnetism), but stimulators themselves can cause interference for our recordings. Some devices may still qualify, and discussion with study nurse may be useful if subject has a pacemaker or similar device.
The subject will have a single 2-3 hour fetal magnetocardiogram at approximately 20 and 27 weeks GA, and again, if medical condition allows, between 30 and 37 weeks GA, then her infant will have an ECG between 0 and 4 weeks of age. Subjects will be paid a nominal fee for their participation each time, as well as transportation reimbursement if >25 miles. For subjects traveling a long distance, the ECG may be performed locally or at home.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03775954
Contact: Mara C Koffarnus, MD | 414-266-4758 | mkoffarn@mcw.edu | |
Contact: Gretchen Eckstein | 414-266-3539 | geckstein@chw.org |
United States, Wisconsin | |
University of Wisconsin - Madison | Recruiting |
Madison, Wisconsin, United States, 53715 | |
Contact: Ronald T Wakai, PhD rtwakai@wisc.edu | |
Contact: Gretchen Eckstein, RN, BSN 414-266-3539 geckstein@chw.org | |
Medical College of Wisconsin | Recruiting |
Milwaukee, Wisconsin, United States, 53226 | |
Contact: Janette F Strasburger, MD 414-266-2000 jstrasbu@mcw.edu | |
Contact: Gretchen C Eckstein, RN, BSN 414-266-3539 (Preferred) geckstein@chw.org |
Principal Investigator: | Janette F Strasburger, MD | Medical College of Wisconsin |
Publications:
Responsible Party: | Janette F. Strasburger, Professor, Medical College of Wisconsin |
ClinicalTrials.gov Identifier: | NCT03775954 |
Other Study ID Numbers: |
PRO00031598 R01HL143485 ( U.S. NIH Grant/Contract ) |
First Posted: | December 14, 2018 Key Record Dates |
Last Update Posted: | March 20, 2023 |
Last Verified: | March 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Only de-identified data can be released |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Fetal Magnetocardiography Stillbirth Intrauterine Fetal Demise Mobile Medical Technologies Fetal Heart Rate Variability Fetal Arrhythmias High Risk Pregnancy |
Pregnancy Fetal Anomaly Fetal Echocardiography Non-Stress Testing New Technology Birth Defects Fetal Research |
Gastroschisis Stillbirth Fetal Death Hydrops Fetalis Heart Diseases Arrhythmias, Cardiac Heart Defects, Congenital Long QT Syndrome Brugada Syndrome Fetofetal Transfusion Congenital Abnormalities Syndrome Death Infant Death Sudden Infant Death |
Disease Pathologic Processes Cardiovascular Diseases Cardiovascular Abnormalities Cardiac Conduction System Disease Pregnancy Complications Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genetic Diseases, Inborn Musculoskeletal Abnormalities Musculoskeletal Diseases Hernia, Abdominal Hernia Pathological Conditions, Anatomical Edema |